Status:
RECRUITING
Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer
Lead Sponsor:
Blida 1 University
Conditions:
Non Metastatic HER2 Positive Breast Cancer
Eligibility:
FEMALE
19+ years
Brief Summary
This study aims to find out how effective and well-tolerated the subcutaneous form of trastuzumab-pertuzumab (known as Phesgo) is when given before surgery (neoadjuvant treatment) to Algerian women wi...
Eligibility Criteria
Inclusion
- Female participants aged 19 years or older.
- Histologically confirmed HER2-positive breast cancer (by immunohistochemistry and/or in situ hybridization), non-metastatic.
- Candidate for neoadjuvant therapy according to local clinical practice.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Left ventricular ejection fraction (LVEF) ≥ 50%.
- Signed written informed consent.
Exclusion
- Evidence of distant metastases.
- Prior anti-HER2 therapy.
- Known contraindications to trastuzumab or pertuzumab.
- Pregnancy or breastfeeding.
- Disease progression during neoadjuvant treatment (if already started).
- Refusal of surgery.
- Withdrawal of consent.
Key Trial Info
Start Date :
March 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT07166185
Start Date
March 1 2025
End Date
December 1 2025
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical oncology department - Anti Cancer Center of Blida
Blida, Algeria, 09000